Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Betting on Friday ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(571)
•••
Comment by IrishCanuckon Jan 05, 2021 12:13pm
187 Views
Post# 32224125

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Betting on Friday ...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Betting on Friday ...Otenaproxesul isn't being fast tracked, that's ATB-352. But I'm happy to be corrected if both are being fast tracked.
--------------------------------------------------
Mugsy, why release news on a Friday though? That's the worst day of the week to generate excitement. Not like we're Berkshire that we're trying to avoid big swings. Any day is a good day but I would pick a Monday or Tuesday

There's no obligation to release a corporate update to the public before going into meetings right? I'll keep my expectations low and expect another delay for the comprehensive corporate update until ATB-352 is ready. I'm in research so see all the time how experiments get delayed and refined, just rewording things to be "perfect" for business people who don't know the difference

I've got enough skin in the game to be happy when it goes up, but keeping my cash ready to avoid rushing in just because it's early January. Good luck all :) 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities